EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Relationship between metastases of differentiated thyroid carcinoma and serum thyrotropin levels


Journal of Clinical Endocrinology and Metabolism 44(6): 1193-1196
Relationship between metastases of differentiated thyroid carcinoma and serum thyrotropin levels
In a group of 113 patients who had undergone thyroid ablation for differentiated thyroid carcinoma, serum levels of TSH were measured 12 and 17 days after discontinuation of triiodothyronine (T3) treatment. On both occasions a wide scattering of TSH levels was found. In patients without metastases, TSH levels varied between 23 and 330 .mu.U[microunits]/ml (mean .+-. SD 142 .+-. 81 .mu.U/ml) at day 12 and between 50 and 380 .mu.U/ml (mean .+-. SD 212 .+-. 95 .mu.U/ml) at day 17. In patients with metastases, TSH levels varied between 35 and 315 .mu.U/ml (mean .+-. SD 145 .+-. 64 .mu.U/ml) at day 12 and between 45 and 330 .mu.U/ml (mean .+-. SD 179 .+-. 74 .mu.U/ml) at day 17. No significant difference between TSH levels of patients with and without metastases was found at day 12, while the difference was significant at day 17. In both groups of patients the increase of TSH levels from day 12 to day 17 was statistically significant. In most patients the reduction or disappearance of metastases by 131I treatment was followed by a significant increase of serum TSH at day 12: before mean .+-. SD 113 .+-. 48 .mu.U/ml, after mean .+-. SD 162 .+-. 62 .mu.U/ml. Only slight changes of TSH levels were found in a group of patients without metastases repeatedly studied during the same period (1st observation mean .+-. SD 148 .+-. 72 .mu.U/ml, 2nd observation mean .+-. SD 149 .+-. 64 .mu.U/ml). Even though hormone production by metastases may influence TSH secretion to some extent, TSH levels after withdrawal of the replacement therapy are mainly related to the individual pituitary response rather than to the presence or absence of metastases. An increase of TSH levels after 131I treatment may be used as a parameter to check the efficiency of 131I treatment itself.

(PDF 0-2 workdays service: $29.90)

Accession: 006297647



Related references

Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. Journal of Clinical Endocrinology and Metabolism 51(3): 513-519, 1980

Relationships between metastases of differentiated thyroid carcinoma and serum thyrotropin (TSH) levels. Journal of Clinical Endocrinology and Metabolism 44(6): 1193-1196, 1977

Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 57(1): 148-151, 1983

A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. Journal of Clinical Endocrinology and Metabolism 90(9): 5047-5057, 2005

Relationships between metastases of differentiated thyroid carcinoma and serum thyroid stimulating hormone levels. Acta Endocrinologica Supplementum 212: 168, 1977

Serum thyrotropin levels after thyroid ablation compared with thyrotropin levels after exogenous bovine thyrotropin implications for iodine 131 treatment of thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism 34(5): 814-818, 1972

Absence of thyrotropin-induced increase in leptin levels in patients with history of differentiated thyroid carcinoma undergoing recombinant human thyrotropin testing. Journal of Endocrinological Investigation 31(10): 888-892, 2009

Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid 14(6): 465-467, 2004

Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 34(5): 814-818, 1972

Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 15(3): 267-273, 2005